{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:27:56Z","timestamp":1780061276663,"version":"3.54.0"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,2,6]],"date-time":"2004-02-06T00:00:00Z","timestamp":1076025600000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2004,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Systemic antibiotics currently used in the treatment of rosacea are sometimes associated with uncomfortable side\u2010effects. Therefore, a need for an effective agent with few side\u2010effects and good patient compliance exists. Azithromycin, a macrolide antibiotic with prolonged mode of action, has recently been found to be an effective alternative in the treatment of inflammatory acne. We planned a study to evaluate the efficacy and safety of azithromycin in rosacea.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> An open\u2010labeled study was performed in a population of 18 patients, with Plewig\u2010Kligman stage 2 rosacea. Patients were given oral azithromycin for 12\u00a0weeks in decreasing doses.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Fourteen subjects completed the trial. The treatment produced therapeutic benefits with regard to total scores as well as inflammatory lesion scores. At the end of 12\u00a0weeks, there was a 75% decrease in total scores (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) and an 89% decrease in inflammatory lesion scores compared with basal values. Improvement continued during the 4\u00a0weeks after treatment. Adverse effects were minimal and well tolerated in most patients.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Azithromycin is a promising agent in the treatment of rosacea with its few side\u2010effects and good patient compliance.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2004.01958.x","type":"journal-article","created":{"date-parts":[[2004,2,6]],"date-time":"2004-02-06T10:12:06Z","timestamp":1076062326000},"page":"151-154","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Therapeutic potential of azithromycin in rosacea"],"prefix":"10.1111","volume":"43","author":[{"given":"\u00d6zg\u00fcr","family":"Bakar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Demir\u00e7ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oya","family":"G\u00fcrb\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,2,6]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625"},{"key":"e_1_2_5_3_2","first-page":"785","volume-title":"Fitzpatrick's Dermatology in General Medicine","author":"Plewig G","year":"1999"},{"key":"e_1_2_5_4_2","first-page":"7","article-title":"Systemic therapy for rosacea: Focus on oral antibiotic therapy and safety","volume":"66","author":"Del Rosso JQ","year":"2000","journal-title":"Cutis"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.4065\/74.6.613"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2000.00749.x"},{"key":"e_1_2_5_7_2","first-page":"34","article-title":"A system for grading rosacea severity","volume":"133","author":"Hendreson CA","year":"1995","journal-title":"Br J Dematol"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70255-Z"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999909116500"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.suppl_2.37"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01975835"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.suppl_2.47"},{"key":"e_1_2_5_13_2","first-page":"156","article-title":"Anti\u2010inflammatory activity of macrolide antibiotics","volume":"292","author":"Ianaro A","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_14_2","first-page":"343","article-title":"Clarithromycin: a new perspective in rosacea treatment","volume":"37","author":"Torresani C","year":"1998","journal-title":"Int J Dermatol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_C.11"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2004.01958.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2004.01958.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T11:34:40Z","timestamp":1696937680000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2004.01958.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["10.1111\/j.1365-4632.2004.01958.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2004.01958.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]},"assertion":[{"value":"2004-02-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}